451 Results for "

HEr2

" in MedChemExpress (MCE) Product Catalog:
Products (451)

451 Results for "HEr2" in MCE Product Catalog:

249
249 Publications Verification
Cat. No.: HY-50767
CAS No.: 571190-30-2
Synonyms: PD 0332991
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
249
249 Publications Verification
Cat. No.: HY-50767A
CAS No.: 827022-32-2
Synonyms: PD 0332991 monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib monohydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
245
245 Cited Publications
Cat. No.: HY-A0065
CAS No.: 827022-33-3
Synonyms: PD 0332991 isethionate
Target:  

CDK

Research Areas:  

Infection Neurological Disease Cancer

Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
229
229 Cited Publications
Cat. No.: HY-50767C
CAS No.: 571189-11-2
Synonyms: PD-0332991 hydrochloride
Target:  

CDK

Research Areas:  

Cancer

Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma .
loading...
    loading...
111
111 Cited Publications
Cat. No.: HY-10261
CAS No.: 850140-72-6
Purity:  99.92%
Synonyms: BIBW 2992
Research Areas:  

Cancer

Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [2] .
loading...
    loading...
111
111 Cited Publications
Cat. No.: HY-10261A
CAS No.: 850140-73-7
Purity:  99.74%
Synonyms: BIBW 2992MA2
Research Areas:  

Cancer

Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [2] .
loading...
    loading...
70
70 Cited Publications
Cat. No.: HY-10211
CAS No.: 75747-14-7
Purity:  99.01%
Synonyms: 17-AAG; NSC 330507; CP 127374
Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...
66
66 Cited Publications
Cat. No.: HY-P9907
CAS No.: 180288-69-1
Synonyms: Anti-Human HEr2, Humanized Antibody
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer [2] . (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
loading...
    loading...
66
66 Cited Publications
Cat. No.: HY-P9907A
CAS No.: 180288-69-1
Synonyms: Anti-Human HEr2, Humanized Antibody (anti-HEr2)

Target:  

ADC Antibodies EGFR

Research Areas:  

Cancer

Trastuzumab (anti-HER2) is a humanized IgG1 monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab (anti-HER2) has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-32721
CAS No.: 698387-09-6
Synonyms: HKI-272
Target:  

EGFR

Research Areas:  

Cancer

Neratinib (HKI-272) is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively .
loading...
    loading...
27
27 Cited Publications
Cat. No.: HY-32721B
CAS No.: 915942-22-2
Synonyms: HKI-272 maleate
Target:  

EGFR

Research Areas:  

Cancer

Neratinib (HKI-272) maleate is an orally available, irreversible, highly selective HER2 and EGFR inhibitor with IC50s of 59 nM and 92 nM, respectively .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-16069
CAS No.: 937263-43-9
Synonyms: Irbinitinib; ARRY-380; ONT-380
Target:  

EGFR

Research Areas:  

Cancer

Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-16069A
CAS No.: 1429755-56-5
Synonyms: Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate
Target:  

EGFR

Research Areas:  

Cancer

Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-104065
CAS No.: 1269662-73-8
Purity:  99.89%
Synonyms: SHR-1258
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib (SHR-1258) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-104065B
CAS No.: 1397922-61-0
Purity:  98.01%
Synonyms: SHR-1258 dimaleate
Target:  

EGFR

Research Areas:  

Cancer

Pyrotinib dimaleate (SHR-1258 dimaleate) is a potent and selective EGFR/HER2 dual inhibitor with IC50s of 13 and 38 nM, respectively .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-13631D
CAS No.: 1599440-33-1
Purity:  99.30%
Synonyms: Exatecan derivative for ADC
Research Areas:  

Cancer

DXd (Exatecan derivative for ADC) is a potent DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM, used as a conjugated drug of HER2-targeting ADC (DS-8201a).
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-135815
CAS No.: 1847461-43-1
Purity:  99.60%
Synonyms: TAK-788; AP32788
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research [2].
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-135815A
CAS No.: 2389149-74-8
Purity:  99.83%
Synonyms: TAK-788 succinate; AP32788 succinate
Target:  

EGFR

Research Areas:  

Cancer

Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research [2].
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-P9912A
CAS No.: 380610-27-5

Target:  

EGFR

Research Areas:  

Cancer

Pertuzumab (anti-HER2), a humanized monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-P9912
CAS No.: 380610-27-5

Target:  

EGFR

Research Areas:  

Cancer

Pertuzumab, a humanized IgG1 monoclonal antibody, is a HER2 dimerization inhibitor for the treatment of metastatic HER2-positive breast cancer.
loading...
    loading...